The SEC has accused former investment adviser senior associate Rakesh Ahuja of using confidential biotech deal information to trade through a relative’s account, generating about $65,000 in alleged ...

Legend Biotech Corporation Sponsored ADR (LEGN) shares ended the last trading session 18.4% higher at $25.07. The jump came on an impressive volume with a higher-than-average number of shares changing ...

Zhengye receives a Nasdaq notice for failing to file its 2024 annual report on time. The company has 60 days to submit a compliance plan to avoid potential delisting. Get special access to three ...

Learning how to trade biotech stocks offers some of the most explosive profit opportunities in the entire market—but also some of its most punishing risks. Biotech stocks can double or triple ...

Biotech has reasserted itself over the past year as drug approvals, obesity and GLP-1 programs, oncology pipelines, and ...

TRINITY BIOTECH ($TRIB) is expected to release its quarterly earnings data on Thursday, May 22nd before market open, per Finnhub. Analysts are expecting revenue of ...

A senior associate allegedly traded biotech deals in a relative's account. The SEC says he pocketed about $65,000.

(RTTNews) - Patience is a virtue - important in all aspects of life, and especially crucial when it comes to investing. As trading expert Steve Burns once said, "Much of our trading comes down to a ...

SANTA ANA, Calif., Oct. 09, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of ...

Oncolytics Biotech (NASDAQ:ONCY – Get Free Report)‘s stock had its “hold” rating reissued by research analysts at Jones Trading in a report released on Friday,Benzinga reports. Several other equities ...

Stramsen Biotech plans to create hundreds of jobs and boost the economy locally and elsewhere, as it welcomes investment banks and law firms. HOUSTON, March 10, 2026 /PRNewswire/ -- Stramsen Biotech ...

Sana Biotechnology (SANA) is back in focus after Mayo Clinic agreed to collaborate on SC451 for type 1 diabetes and invest up to US$50 million, linking clinical expertise with fresh capital support.